Key result
Aldosterone synthase inhibition may complement existing hypertension therapies and reshape treatment algorithms pending future trials.
Why the study?
Do aldosterone synthase inhibitors reduce blood pressure in patients with resistant and uncontrolled hypertension?
Do aldosterone synthase inhibitors reduce blood pressure in patients with resistant and uncontrolled hypertension?
Aldosterone synthase inhibition represents a promising novel therapeutic strategy for resistant and uncontrolled hypertension, offering consistent blood pressure reductions.
PURPOSE OF REVIEW: Despite widespread use of renin-angiotensin-aldosterone system blockade, resistant and uncontrolled hypertension remain common, highlighting the need for novel therapeutic strategies. Growing recognition of aldosterone excess as a central driver of vascular, cardiac, and kidney injury has renewed interest in targeting this pathway. Recent advances in highly-selective aldosterone synthase inhibition (ASI) suggest this is a clinically viable approach. RECENT FINDINGS: ASIs, including baxdrostat and lorundrostat, demonstrate consistent blood pressure reductions of approximately 8-12 mmHg when administered in addition to standard antihypertensive therapy across phase 2 and phase 3 trials. These drugs may overcome limitations of mineralocorticoid receptor antagonists by suppressing aldosterone production upstream, mitigating aldosterone escape, and reducing adverse effects. There may also be benefits among patients with chronic kidney disease, primary aldosteronism, and heart failure with preserved ejection fraction, supporting a broader cardiorenal role. SUMMARY: Aldosterone synthase inhibition represents an advance in hypertension therapeutics. If ongoing and future outcome-driven trials confirm cardiovascular and renal benefit, ASIs may reshape treatment algorithms, complement existing renin-angiotensin-aldosterone-based strategies, and enable more precise targeting of aldosterone-mediated disease.
No takes yet. Share an insight, caveat, or question.
Alkhatib et al. (2026) conducted a review in hypertension. Aldosterone synthase inhibitors (baxdrostat and lorundrostat) vs. standard antihypertensive therapy was evaluated on blood pressure reduction (8-12 mmHg reduction). Aldosterone synthase inhibitors, including baxdrostat and lorundrostat, demonstrate consistent blood pressure reductions of approximately 8-12 mmHg when added to standard antihypertensive therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: